MYGN Stock Recent News

Highlights First quarter 2025 revenue of $196 million  declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year.

Initiate Buy on Myriad Genetics, trading near multi-year lows with potential for significant growth driven by new offerings and stable core franchises. Strong financials with $158 million in liquidity, improving margins, and a path to profitability by 2025; 2024 revenue grew 11% YoY to $838 million. Key growth drivers include GeneSight, MyRisk, Prolaris, Precise MRD, and FirstGene; significant market opportunities in psychiatric PGx, hereditary cancer, prostate prognostics, MRD, and prenatal genetics.

More than half say genetic testing for mental health medications could reduce concerns More than half say genetic testing for mental health medications could reduce concerns

Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of Precise™ MRD

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035.

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight ® Psychotropic Test. “Millions of Americans face major depressive disorder each year, and the GeneSight test provides genetic insights that may help healthcare providers personalize the selection of mental health medications,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly's entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4).

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies.

Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.

Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.